Biogen Receives FDA Approval For Aduhelm
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178
Eiger BioPharma’s Single Dose Of Peginterferon Lambda Cuts Risk Of COVID-19-Related Hospitalizations, Deaths
Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in…
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
Aligos Therapeutics Inc (NASDAQ:ALGS) announced a portfolio reprioritization, with priorities focused on the rapid advancement of its clinical NASH (ALG-055009)…
AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus
AbbVie Inc (NYSE:ABBV) has reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the consensus of $3.56. Overall…
Nexcella, A Subsidiary Of Immix Biopharma, Presents 42-Patient Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5th European Car T-Cell Meeting
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the
Gilead Highlights Kite’s Tecartus CAR T-Cell Therapy Data In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial
-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months --
FDA Granted Mesoblast Regenerative Medicine Advanced Therapy Designation granted For Rexlemestrocel-L In Chronic Low Back Pain
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Food and Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent
Cara Therapeutics Announces Results From The KOMFORT Phase 2 Trial Of Oral Difelikefalin For The Treatment Of Pruritus In Notalgia Paresthetica Published In The New England Journal Of Medicine
Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the New England
Analyst Reiterates This Alzheimer’s Candidate As Top Idea For 2023
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ:BTAI) from $24 to $38, with a Buy rating. Since the analyst’s previous…
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
After the markets closed on Tuesday, VistaGen Therapeutics Inc (NASDAQ:VTGN) reported a Q3 FY23 net loss of $(9.8) million or $(0.05) per…